CLINICAL TRIALS AND OBSERVATIONS Improved outcome in central nervous system aspergillosis, using voriconazole treatment

نویسندگان

  • Stefan Schwartz
  • Markus Ruhnke
  • Patricia Ribaud
  • Lawrence Corey
  • Timothy Driscoll
  • Oliver A. Cornely
  • Ulrich Schuler
  • Irja Lutsar
  • Peter Troke
  • Eckhard Thiel
چکیده

The mortality of central nervous system (CNS) aspergillosis approaches 100%, requiring improved therapies. Voriconazole gives superior efficacy and survival in invasive aspergillosis, compared with amphotericin B. Also, in contrast to other antifungal drugs, voriconazole penetrates well into the CNS. We evaluated, retrospectively, the outcome and survival of 81 patients who were treated with voriconazole for definite (n 48) or probable (n 33) CNS aspergillosis. Complete and partial responses were recorded in 35% of patients and varied by the underlying disease group: hematologic malignancies (54%), other underlying conditions (50%), chronic immunosuppression (45%), solid organ transplantation (36%), and hematopoietic stem cell transplantation (16%). Thirty-one percent of patients survived CNS aspergillosis for a median observation time of 390 days. There were 31 patients who underwent neurosurgical procedures, including craniotomy/abscess resection (n 14), abscess drainage (n 12), ventricular shunt (n 4), and Ommaya-reservoir (n 1). Multifactorial analysis revealed that neurosurgery was associated with improved survival (P .02). Patients who underwent hematopoietic stem cell transplantation had a poorer survival (P .02), but 7 (22%) of 32 survived for a median of 203 days. We conclude from this large cohort of patients that voriconazole treatment together with neurosurgical management, whenever feasible, is currently the best approach to treat patients with CNS aspergillosis. (Blood. 2005;106:2641-2645)

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL TRIALS AND OBSERVATIONS Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole

We here investigate the occurrence of fluoride intake-associated alterations in patients with hematologic disease on triazol antifungal medication. Clinical, laboratory, and radiology data of overall 43 patients with hematologic malignancies taking voriconazole (n 20), posaconazole (n 8), and itraconazole (n 4), and a hematologic patient control group (n 11) are described. Bone pain and radiolo...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study

We assessed the outcome of children with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) receiving contemporary risk-based therapy by evaluating clinical and biologic features and outcome of children with ALL, with or without DS, enrolled in Children’s Cancer Group (CCG) protocols between 1983 and 1995. Comparison of characteristics of children with ALL with (ALL-DS; n 179) or without...

متن کامل

Regular Article CLINICAL TRIALS AND OBSERVATIONS Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study

• CNS involvement at relapse/ progression in PTCL occurred at a frequency similar to what is seen in aggressive B-cell lymphomas. • Outcome after relapse is generally very poor in patients with PTCL and is not significantly altered by presence of CNS involvement at relapse. Central nervous system (CNS) relapse in non-Hodgkin lymphoma (NHL) carries a very poor prognosis. Risk factors and outcome...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents

Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents Mitchell S. Cairo,1 Mary Gerrard,2 Richard Sposto,3 Anne Auperin,4 C. Ross Pinkerton,5 Jean Michon,6 Claire Weston,7 Sherrie L. Perkins,8 Martine Raphael,9 Keith McCarthy,10 and Catherine Patte,4 on behalf of the FAB LMB96 Internat...

متن کامل

Evidence-Based Treatment for HIV-Associated Dementia and Cognitive Impairment: Why So Little?

The Abacavir Trial in Context HIV-associated dementia (HAD) and milder forms of cognitive impairment produce a spectrum of disability that ranges from complete inability to care for oneself to reduced work efficiency and quality of life. HAD is believed to arise from a confluence of adverse effects on neuronal function resulting both from HIV itself and from disturbances in cellular signalling,...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2005